FDA
-
-
-
-
-
-
-
FDA clears expansion of Creative Medical's back pain trial
-
-
-
-
-
-
-
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
-
-
-
-
-
-
-
Creative Medical Technology Holdings, Inc (CELZ) Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
-
-
-
-
-
-
-
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Trea
-
-
-
-
-
-
-
Creative Medical Technology (CELZ) Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
-
-
-
-
-
-
-
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Low
-
-
-
-
-
-
-
Creative Medical Technology Holdings (CELZ) Reports Positive Top-Line Results for Type 2 Diabetes Study
-
330,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
